94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1541364
Trends and Hotspots in Pulmonary Fibrosis Biomarker Research: A Bibliometric Analysis
Provisionally accepted- 1Zhangjiajie Hospital Affiliated to Hunan Normal University, Zhangjiajie, China
- 2Changsha Central Hospital, Changsha, Hunan Province, China
- 3Hunan Hospital of Traditional Chinese Medicine, Changsha, Hunan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
BackgroundPulmonary fibrosis is a fatal disease characterized by progressive scarring of lung tissue, with a complex pathogenesis and limited therapeutic options. The identification of robust biomarkers is critical for addressing key clinical challenges, including delayed diagnosis and poor prognostic assessment.MethodsThis study systematically analyzes global research trends and emerging hotspots in pulmonary fibrosis biomarkers by examining literature from 2001 to 2024 indexed in the Web of Science Core Collection. Utilizing a suite of bibliometric tools including VOSviewer, CiteSpace, Bibliometrix, Scimago Graphica, and OriginPro 2021, this work provides the first comprehensive insight into the evolving landscape of biomarker research in pulmonary fibrosis.ResultsThis study included a total of 2,519 articles and reviews related to pulmonary fibrosis biomarkers. Since 2005, publication trends in this field have steadily increased. Research on pulmonary fibrosis biomarkers has involved 71 countries, 3,036 institutions, 760 journals, and over 14,000 researchers. China produced the highest number of publications (n = 535, 21.2%, TLCS = 459), followed by the United States (n = 529, 21%, TLCS = 3,527) and Japan (n = 270, 10.7%, TLCS = 1,279), with the United States exerting the greatest influence. The UNIVERSITY OF CALIFORNIA SYSTEM (n = 164) and HARVARD UNIVERSITY (n = 141) contributed the largest bodies of work. The most prolific authors in this domain are BARGAGLI E (n = 45), MAHER TM (n = 42), and MARTINEZ FJ (n = 32). The AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE is widely regarded as the leading journal in this field. In recent years, research has increasingly focused on macrophages, computed tomography, and Muc5b promoter polymorphism, among other areas. The concept of “double blind” reflects the translational trend of biomarkers toward clinical applications, particularly their potential utility in acute exacerbations of pulmonary fibrosis, interstitial pulmonary fibrosis, cystic pulmonary fibrosis, and radiation-induced pulmonary fibrosis.ConclusionThe clinical application of gene and imaging biomarkers achieved through the integration of multiple parameters and multi-omics fusion represents a promising future trend and emerging hotspot in pulmonary fibrosis biomarker research.Keywords: Pulmonary Fibrosis; Biomarkers; Disease Management; Bibliometric Analysis;MUC5B
Keywords: Pulmonary Fibrosis, biomarkers, Disease Management, bibliometric analysis, MUC5B
Received: 07 Dec 2024; Accepted: 09 Apr 2025.
Copyright: © 2025 Wang, Huang, Tan, Zhang, Xiao, Xia, Kang and Lei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mingsheng Lei, Zhangjiajie Hospital Affiliated to Hunan Normal University, Zhangjiajie, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.